Post-marketing reevaluation for potential quality risk and quality control in clinical application of traditional Chinese medicines.
- Author:
Hong-jiao LI
;
Li-yun HE
;
Bao-yan LIU
- Publication Type:Journal Article
- MeSH:
Drugs, Chinese Herbal;
adverse effects;
economics;
therapeutic use;
Humans;
Medicine, Chinese Traditional;
Product Surveillance, Postmarketing;
methods;
Quality Control;
Randomized Controlled Trials as Topic;
Respiratory Tract Infections;
drug therapy
- From:
China Journal of Chinese Materia Medica
2015;40(12):2461-2463
- CountryChina
- Language:Chinese
-
Abstract:
The effective quality control in clinical practices is an effective guarantee for the authenticity and scientificity of the findings. The post-marketing reevaluation for traditional Chinese medicines (TCM) focuses on the efficacy, adverse reaction, combined medication and effective dose of drugs in the market by expanded clinical trials, and requires a larger sample size and a wider range of patients. Therefore, this increases the difficulty of quality control in clinical practices. With the experience in quality control in clinical practices for the post-marketing reevaluation for Kangbingdu oral for cold, researchers in this study reviewed the study purpose, project, scheme design and clinical practice process from an overall point of view, analyzed the study characteristics of the post-marketing reevaluation for TCMs and the quality control risks, designed the quality control contents with quality impacting factors, defined key review contents and summarized the precautions in clinical practices, with the aim to improve the efficiency of quality control of clinical practices. This study can provide reference to clinical units and quality control-related personnel in the post-marketing reevaluation for TCMs.
